Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
RXRX · Why this verdict
Why Recursion Pharmaceuticals (RXRX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score3.8/10
ConfidenceHIGH
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Recursion Pharmaceuticals is an artificial intelligence-driven drug discovery company with analyst targets implying 102% upside and 3 of the last 4 quarters showing positive earnings surprises, but a confirmed death cross, 33% short interest, and near-zero quality scores reflect deep fundamental concerns about the pre-revenue business model.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Analysts maintain targets implying approximately 102% upside from the current price of $3.29, with a consensus sentiment reflecting belief that the company's artificial intelligence-based drug discovery platform represents a structural advantage in identifying novel drug candidates at scale. Sentiment breakdown | Analyst consensus price target remains above $6, at least 80% above the current price, over the next 12 months as platform partnership milestones sustain the bull case. | →Stable |
| CounterAI-based drug discovery is a pre-proof-of-concept technology at the clinical level; the 75.7% implied upside in analyst targets reflects speculative option value, and clinical trial failures could cause rapid and severe target price compression. | ||
The company beat earnings estimates in 3 of the last 4 quarters with an average positive surprise of approximately 9.4%, including a 33% beat in the February 2026 quarter, indicating losses are coming in less severe than analysts modeled. Earnings | EPS surprise remains positive in at least 2 of the next 4 quarters, indicating continued beat-versus-estimates pattern as the company manages its cash burn rate. | →Stable |
| CounterPositive EPS surprises in pre-revenue biotechs typically mean losses were smaller than feared rather than genuine profitability progress; the absolute loss per share of negative $0.22 still represents substantial ongoing cash consumption. | ||
A confirmed death cross with the 50-day moving average well below the 200-day and the 200-day declining at negative 7.8% per month represents one of the most severe downtrends in the group, indicating sustained institutional selling at the current price level. Momentum breakdown | The 200-day moving average slope declines by less than 2% per month within 6 months, indicating the downtrend is stabilizing ahead of a potential reversal. | →Stable |
| CounterA moving average slope of negative 7.8% per month means the 200-day is declining rapidly, which historically requires a sustained period of price appreciation well above the 200-day level before slope turns positive, a long recovery path from $3.29. | ||
Short interest at 33% of float is among the highest in the universe covered, with a put-to-call ratio of 2.56 and implied volatility of 124%, indicating extremely high bearish positioning that could fuel a powerful short squeeze if positive clinical data emerges. Risk breakdown | Short interest falls below 20% within 12 months following a positive clinical milestone or partnership announcement that forces short sellers to cover. | →Stable |
| Counter33% short interest in a cash-burning pre-revenue biotech with a Piotroski score of 2 out of 9 likely reflects fundamental conviction among short sellers that the AI drug discovery model will not produce approved drugs on the timeline implied by the current valuation. | ||
Analysts maintain targets implying approximately 102% upside from the current price of $3.29, with a consensus sentiment reflecting belief that the company's artificial intelligence-based drug discovery platform represents a structural advantage in identifying novel drug candidates at scale.
→StableSentiment breakdown
- Expectation
- Analyst consensus price target remains above $6, at least 80% above the current price, over the next 12 months as platform partnership milestones sustain the bull case.
CounterAI-based drug discovery is a pre-proof-of-concept technology at the clinical level; the 75.7% implied upside in analyst targets reflects speculative option value, and clinical trial failures could cause rapid and severe target price compression.
The company beat earnings estimates in 3 of the last 4 quarters with an average positive surprise of approximately 9.4%, including a 33% beat in the February 2026 quarter, indicating losses are coming in less severe than analysts modeled.
→StableEarnings
- Expectation
- EPS surprise remains positive in at least 2 of the next 4 quarters, indicating continued beat-versus-estimates pattern as the company manages its cash burn rate.
CounterPositive EPS surprises in pre-revenue biotechs typically mean losses were smaller than feared rather than genuine profitability progress; the absolute loss per share of negative $0.22 still represents substantial ongoing cash consumption.
A confirmed death cross with the 50-day moving average well below the 200-day and the 200-day declining at negative 7.8% per month represents one of the most severe downtrends in the group, indicating sustained institutional selling at the current price level.
→StableMomentum breakdown
- Expectation
- The 200-day moving average slope declines by less than 2% per month within 6 months, indicating the downtrend is stabilizing ahead of a potential reversal.
CounterA moving average slope of negative 7.8% per month means the 200-day is declining rapidly, which historically requires a sustained period of price appreciation well above the 200-day level before slope turns positive, a long recovery path from $3.29.
Short interest at 33% of float is among the highest in the universe covered, with a put-to-call ratio of 2.56 and implied volatility of 124%, indicating extremely high bearish positioning that could fuel a powerful short squeeze if positive clinical data emerges.
→StableRisk breakdown
- Expectation
- Short interest falls below 20% within 12 months following a positive clinical milestone or partnership announcement that forces short sellers to cover.
Counter33% short interest in a cash-burning pre-revenue biotech with a Piotroski score of 2 out of 9 likely reflects fundamental conviction among short sellers that the AI drug discovery model will not produce approved drugs on the timeline implied by the current valuation.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.5 |
| FCF quality | 0.0 |
| Moat | 2.5 |
| Piotroski F | 2.2 |
- ▸Cash-burning: FCF -268% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
1.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 4.0 |
| OBV | 1.0 |
| MA position | 1.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -6.9%/30d — confirmed downtrend
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 101%
Insider
3.9/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Modest insider selling — $1,092,788 (0.064% of mkt cap)
Peer rank
1.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.2 |
| quality rank | 1.7 |
| growth rank | 1.7 |
Technical
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 5.3 |
| support resistance | 6.8 |
| 52w position | 0.0 |
Risk (lower is worse)
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.2 |
| days to cover | 0.1 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| max pain risk | 3.0 |
| beta | 7.0 |
| debt equity | 0.0 |
- ▸High short interest justified: 33%
- ▸High IV: 113%
- ▸Above max pain $0
Catalyst
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 7.2 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- ASYMMETRY:5.2>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:41d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:1.9<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
5.20
Upside
+75.1%
Downside
14.5%
Sizing output
AVOID
SetupFALLING_KNIFE — Death cross, below all MAs, RSI 34, MACD bearish
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $1.7B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 6.6 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:1.9<4.5.
The strongest dimensions are Sentiment at 6.6, Catalyst at 6.0, and Value at 5.4; the weakest are Quality at 1.5, Peer rank at 1.7, and Momentum at 1.9. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 5.20 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Analysts maintain targets implying approximately 102% upside from the current price of $3.29, with a consensus sentiment reflecting belief that the company's artificial intelligence-based drug discovery platform represents a structural advantage in identifying novel drug candidates at scale.
Trip ifAnalyst consensus price target falls below $4, more than 30% below the current target of approximately $5.78, indicating widespread downgrade activity.
- P2The company beat earnings estimates in 3 of the last 4 quarters with an average positive surprise of approximately 9.4%, including a 33% beat in the February 2026 quarter, indicating losses are coming in less severe than analysts modeled.
Trip ifEPS surprise falls below 0% in at least 3 of the next 4 quarters, indicating the improving beat pattern has reversed.
- P3A confirmed death cross with the 50-day moving average well below the 200-day and the 200-day declining at negative 7.8% per month represents one of the most severe downtrends in the group, indicating sustained institutional selling at the current price level.
Trip ifThe 200-day moving average slope worsens beyond negative 10% per month for more than 2 consecutive months, indicating the downtrend is accelerating.
- P4Short interest at 33% of float is among the highest in the universe covered, with a put-to-call ratio of 2.56 and implied volatility of 124%, indicating extremely high bearish positioning that could fuel a powerful short squeeze if positive clinical data emerges.
Trip ifShort interest rises above 40% of float, more than 7 percentage points above the current 33%, indicating increased short conviction.